Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer [Rapid Communication]

Conclusion
Durvalumab demonstrated a manageable safety profile and evidence of meaningful clinical activity in PD-L1–positive patients with UBC, many of whom were heavily pretreated.

Source: Journal of Clinical Oncology - August 30, 2016 Category: Cancer & Oncology Authors: Massard, Gordon, Sharma, Rafii, Wainberg, Luke, Curiel, Colon-Otero, Hamid, Sanborn, ODonnell, Drakaki, Tan, Kurland, Rebelatto, Jin, Blake-Haskins, Gupta, Segal Tags: Phase I and Clinical Pharmacology, Translational Oncology, Rapid Communications, Rapid Communications, Other, Phase I and Clinical Pharmacology Source Type: research